You can narrow down the results using the filters
-
Feasibility of the Australian Auscultation for Cardiopulmonary Assessment (AUSCA) Patch on Cardiology Patients
Expand descriptionThe AUSCA patch is a non-invasive diagnostic tool that uses adhesive tape to stay insitu whilst in use. The patch can record, heart, lung and pulse waveforms using sound waves. The main aim of the study is to assess the ability of the AUSCA patch to record various observations, waveforms and haemodynamic measurements during rest and exercise of patients with cardiac disease. We would also like to analyse the waveforms gained from the AUSCA patch on patients who have an implanted Mechanical Circulatory Support (MCS) Device to gain more insight into the pump's function.
-
Expanding access to hepatitis C care by offering rapid finger prick testing at community pharmacies for adults with hepatitis C risk factors.
Expand descriptionThe aims of this study are to investigate new and novel models of care to improve ease of access to HCV testing and treatment for people who inject drugs (PWID) within community pharmacies. The study will evaluate the effectiveness, economic impact, and sustainability of outreach nurses collaborating with community pharmacists who dispense Opiate Agonist Therapy (OAT). Building a network of community pharmacies engaged in hepatitis C testing and care will improve access to diagnosis and treatment for people who inject drugs, leading to higher rates of diagnosis, treatment initiation, and cure in a cost-effective and sustainable way.
-
Effect of mussel salts and mussel oil on plasma plasma fatty acid levels in healthy adults
Expand descriptionMarine omega-3 oils have a short shelf life and poor bioavailability due to oxidation. This instability limits their effectiveness and increases manufacturing costs due to the need for softgel encapsulation and stabilising aids. There is a clear industry need for a solution that extends shelf life, improves bioavailability, and enables more versatile product formulations. NETech has developed a proprietary technology that converts marine oils into a stable powder form, significantly reducing oxidation and increasing bioavailability. This technology eliminates the need for additional stabilisers and softgel formats, offering a purer and more versatile omega-3 product compared to existing technologies. This project aims to compare the effect of consuming mussel oil and mussel powder on plasma omega-3 polyunsaturated fatty acid levels.
-
Advancing Care Through Injury Outcome Navigators
Expand description -
Topical anti-Inflammatory Medication, for the management of Toe And Midfoot osteoarthritis: the TIMTAM randomised controlled trial
Expand descriptionThis randomised control trial will compare the effects of topical non-steroidal anti inflammatory drug (NSAID) to a sham topical gel in people with painful foot osteoarthritis (OA). The primary objective is to determine whether daily use of a topical NSAID gel leads to significantly greater reductions in foot OA pain with walking, compared to a sham gel, at 6 weeks. The secondary objectives are to determine whether daily use of a topical NSAID gel leads to significantly greater benefits on other clinical outcomes (physical function, other measures of foot OA pain, global ratings of change, health-related quality of life, and physical activity levels), compared to a sham gel, at 6 weeks, and evaluate the extent of use and clinical outcomes in a subsequent 6 week follow up period when use was deemed as needed, at 12 weeks.
-
Peri-operative antibiotic irrigation of bowel lumen in colorectal surgery patients for the prevention of anastomotic leakage: a feasibility study
Expand descriptionThe AWASH study aims to investigate the feasibility of applying an antibiotic wash to the bowel during surgery, with a short course of post-operative irrigation in some patients, for adults having planned colorectal surgery where the bowel is rejoined. Who is it for? You may be eligible for this study if you are an adult undergoing elective colorectal resection with primary anastomosis. Study details Participants will be randomly allocated to receive either the study treatment or standard care. The study treatment involves washing the bowel during surgery with antibiotics, and for patients undergoing an anastomosis within 15cm of the anus, a trans-anal drainage tube will be placed intra-operatively to facilitate antibiotic washing on postoperative days 1 and 2. Outcomes on success of delivery of the treatment and patient complications will be collected. It is hoped that findings from this study will help clinicians and researchers determine whether the intervention and study processes can be delivered safely and successfully to inform a larger future trial.
-
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Drug-Drug Interactions of NB-9402 in Healthy Adult Volunteers - Part C Drug-Drug Interactions
Expand descriptionThis Phase 1 study is testing a new drug called NB-9402. The study drug NB-9402 is being developed by Nura Bio Inc, as a potential treatment for diseases of the nervous system. The study will evaluate the potential drug-drug interactions of NB-9402 with repaglinide and midazolam.
-
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Drug-Drug Interactions of NB-9402 in Healthy Adult Volunteers - Part A and B
Expand descriptionThis Phase 1 study is testing a new drug called NB-9402. The study drug NB-9402 is being developed by Nura Bio Inc. as a potential treatment for diseases of the nervous system. This study will assess the safety and tolerability of NB-9402 when given as single and multiple oral doses in healthy adult volunteers.
-
A Multicenter, Phase 2/3, Dose Range Finding Study to Evaluate the Efficacy and Safety of Atumelnant in Adults with ACTH-Dependent Cushing’s syndrome (ADCS) Including an Open-Label Extension for Long-Term Assessment (EQUILIBRIUM ADCS) – Part C
Expand descriptionThe purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of atumelnant in participants with ADCS. This entire study consists of 3 parts: Part A (not described in this registration), Part B (not described in this registration), and Part C. In Part C is an open-label long-term portion of the study. All participants will receive atumelnant by mouth for up to 2 years, using a concomitant B&R treatment regimen. Up to 201 participants will be included (up to 186 from Parts A and B, and approximately 15 new participants).
-
A Multicenter, Phase 2/3, Dose Range Finding Study to Evaluate the Efficacy and Safety of Atumelnant in Adults with ACTH-Dependent Cushing’s syndrome (ADCS) Including an Open-Label Extension for Long-Term Assessment (EQUILIBRIUM ADCS) – Part B
Expand descriptionThe purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of atumelnant in participants with ADCS. This entire study consists of 3 parts: Part A (not described in this registration), Part B, and Part C (not described in this registration). In Part B of the study, participants will be randomized into 2 arms: - Atumelnant and steroid medication. The atumelnant dose will be determined based on data from Part A. - Placebo atumelnant and placebo steroid. Participants will be randomized in a 2 to 1 ratio (for every 2 participants who receive atumelnant, 1 participant will receive placebo) and will receive the study drug (atumelnant or placebo) by mouth for 12 weeks. Whether a participant receives atumelnant or placebo will be determined by chance (like drawing straws). This part of the study is double blind, the participant, their caregiver(s), and the study doctors will not know which treatment is being given (blinded to treatment). After participation in Part B of the study, participants might be able to stay in the study in Part C (open-label extension where all participants will receive atumelnant and steroid replacement therapy) if, in the Investigator’s opinion, they would benefit from it.